Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisolone 21-phosphate is a synthetic glucocorticoid corticosteroid ester used primarily for its anti-inflammatory and immunosuppressive effects. It acts by binding to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory pathways. This drug is indicated for a wide range of conditions including allergic states, dermatologic diseases, edematous states (such as nephrotic syndrome), endocrine disorders (including adrenocortical insufficiency), gastrointestinal diseases, hematologic disorders, neoplastic diseases (as palliative therapy), nervous system conditions (such as multiple sclerosis exacerbations), ophthalmic diseases (inflammatory eye conditions), respiratory diseases (like asthma), and rheumatic disorders. Prednisolone phosphate is often preferred in situations where rapid onset or parenteral administration is needed due to its water solubility[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisolone-21-phosphate.